Director, Parkinson’s Disease and Movement Disorder Center, University of South Florida
Adjunctive Treatments and Apomorphine for Treatment of Parkinson Disease
Panelists discuss how adjunctive therapies play a crucial role in managing Parkinson disease symptoms, with a particular focus on apomorphine’s unique position in the treatment landscape due to its distinct dopamine receptor binding profile compared with other dopaminergic agents.
Advanced Treatment Options in Parkinson Disease
Panelists discuss how physicians typically consider advanced Parkinson disease treatments when conventional therapies fail to adequately control motor fluctuations, highlighting challenges such as adverse effects, device-related complications, and patient selection criteria.
Conversations About Off Time In Patients With Parkinson Disease
Panelists discuss how physicians approach conversations about off time with patients with Parkinson disease, balancing clinical assessment with patient education and shared decision-making.
Recognition of Off Episodes in Parkinson Disease
Panelists discuss how understanding and communication of off episodes for patients with Parkinson disease varies widely in clinical settings, often hindering optimal symptom management.
Dyskinesia and Patient Communication in Parkinson Disease
April 28th 2025Panelists discuss how early recognition of dyskinesia symptoms, ongoing patient-clinician communication, and individualized treatment strategies are key to effectively managing Parkinson disease and improving patients’ quality of life.
Adjusting and Changing Treatment Regimens in Parkinson Disease
Panelists discuss how treatment changes in Parkinson disease are necessitated by disease progression, diminishing medication effectiveness, and emerging motor complications, examining a physician’s systematic approach to treatment adjustments and the range of available options for managing off fluctuations.
Off Fluctuations in Parkinson Disease
Panelists discuss how off fluctuations in Parkinson disease become increasingly prevalent as the disease progresses, significantly impacting patient quality of life through reduced mobility, independence, and overall well-being.
Significance of Newly Approved IPX203 for Parkinson Disease
August 12th 2024In this opening segment, Hauser and Fernandez discussed the FDA approval of IPX203, a new long-acting levodopa formulation for Parkinson disease, highlighting its significance in improving treatment options and patient compliance.
Unmet Needs and Improving Diagnosis of Dyskinesia in Parkinson Disease
The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.
Surgical Options and Emerging Treatments for Parkinson Disease
Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.
Use of Other Amantadine Formulations in Parkinson Disease
The expert neurology panel shares their clinical experience with different formulations of amantadine in management of dyskinesia in patients with Parkinson disease.
Amantadine DR/ER for Dyskinesia in Parkinson Disease: Safety Profile and Ideal Patient
The expert panel reviews the safety profile of amantadine DR/ER and who may be an ideal patient for its use in patients with Parkinson disease experiencing dyskinesia.
Studies With Amantadine-DR/ER for Treatment of Dyskinesia
The expert neurology panel discusses clinical trial data of amantadine-DR/ER in treatment of dyskinesia and OFF episodes in Parkinson disease.
Amantadine Formulations in Treatment of Dyskinesia in Parkinson Disease
Drs William G. Ondo and Rajesh Pahwa analyze the pharmacokinetics of different formulations of amantadine for treatment of dyskinesia in Parkinson disease.
Treatment of Dyskinesia in Patients with Parkinson’s Disease
Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.
Challenges in Balancing Treatment of OFF Episodes and Dyskinesia in Parkinson Disease
The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.
Diagnosis of Dyskinesia and Impact on Quality of Life of Patients With Parkinson Disease
The expert panel shares strategies for accurate clinical diagnosis of dyskinesia in patients with Parkinson disease and discusses how dyskinesia may impact the quality of life.